✦ LIBER ✦

Lack of cardiotoxicity in metastatic breast cancer (MBC) patients (pts) receiving doxorubicin/Paclitaxel (DOX/PAC) combination

✍ Scribed by Osmanova, L.; Stecenko, A.; Stenina, M.; Kassil, V.; Garin, A.; Tjulandin, S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5072 POSTER First-Line Bevacizumab (Bev)

✍ Foerster, F.; Aktas, B.; Geberth, M.; Tschechne, B.; Schneeweiss, A.; Salat, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Quality of life (QoL) improvements in 14

✍ C. Testa; F. Martins; D. GonÁalves; C. Huttener; O. Aguiar; A. Oliveira; C. Pere 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 43 KB

2009 POSTER Safety of the combination of

✍ A. Storniolo; M. Koehler; A. Preston; E. Rappold; J. Byrne; S. Stein; M. Ewer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

5074 First-line bevacizumab (bev) plus p

✍ F. Foerster; M. Geberth; C. Schumacher; A. Schneeweiss; R. Weinberg; L. Hahn; M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

PP-7-5 phase II study of paclitaxel (P)

✍ Ch. Thomssen; H.-J. Lück; A. du Bois; B. Lisboa; M. Untch; G. Köhler; D. Hecker; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Phase I/II trial of oral UFT/Leucovorin

✍ Klaassen, U.; Lang, S.; Borquez, D.; Oberhoff, C.; Benner, S.; Harstrick, A.; Se 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 322 KB